Business Context and Reporting Period
Company: Amarin Corporation plc (Amarin)
Filing Type: Form 20-F Annual Report
Reporting Period: Fiscal year ended December 31, 2001
Business Overview: Amarin is a specialty pharmaceutical company focused on neurology and pain management. Operations are conducted through its US subsidiary, Amarin Pharmaceuticals, Inc. (API), for marketing and sales, and its Swedish subsidiary, Amarin Development AB, for drug delivery technology R&D. The company shifted its strategic focus in 1999 from transdermal patch technology to acquiring FDA-approved products and developing neurology/pain management franchises.
Key Financial Metrics (Year Ended Dec 31, 2001)
| Metric | Value (GBP '000) | Value (USD '000 approx) |
|---|---|---|
| Total Revenues | 36,927 | ~53,740 |
| Gross Profit | 22,193 | ~32,290 |
| Gross Margin | 60% | - |
| Operating Loss (Continuing Ops) | (3,487) | ~(5,075) |
| Net Loss (UK GAAP) | (3,269) | ~(4,757) |
| Net Loss (US GAAP) | (3,725) | ~(5,421) |
| Cash and Cash Equivalents | 20,688 | ~30,110 |
| Short-Term Debt (Related Party) | 30,919 | ~45,000 |
| Long-Term Debt (Related Party) | 4,466 | ~6,500 |
Note: USD conversions are approximate based on the year-end rate of £1 = $1.4554.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by £26.4 million (251%) from £10.5 million in 2000 to £36.9 million in 2001. This was primarily driven by the acquisition of US marketing rights to Permax (pergolide mesylate) in May 2001, which contributed £18.6 million in revenue for the year.
- Operating Expenses: Total operating expenses surged by 180% to £25.8 million. This increase was largely due to a £12.5 million amortization charge related to the initial sales and marketing rights for Permax, as well as costs associated with establishing a 24-person US neurology sales force.
- Profitability: Despite significant revenue growth, the company reported a net loss of £3.3 million (UK GAAP) compared to a net profit of £1.7 million in 2000. The 2000 profit included £2.5 million from discontinued operations (transdermal business), whereas 2001 included a loss on the disposal of South American transdermal assets.
- Discontinued Operations: The company completed the divestiture of its South American transdermal business in November 2001, resulting in a loss on disposal of £0.9 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Permax Strategy: The Board approved the exercise of the option to acquire Elan's full rights to Permax in March 2002, subject to Lilly's consent. This requires additional fixed payments of $37.5 million and ongoing royalties.
- Pipeline: The company is pursuing FDA approval for Zelapar (Parkinson's disease) and LAX-101 (Huntington's disease). An NDA for Zelapar is expected in the first half of 2002, and LAX-101 Phase III trials are ongoing with an anticipated NDA filing in 2003.
- Liquidity: Management expects to generate positive cash flow from operations but acknowledges a significant need for additional capital to repay a $45 million loan from Elan due in September 2002 and to fund the Permax option exercise.
Risks and Contingencies
- Debt Maturity: A $45 million loan from an Elan affiliate matures on September 30, 2002. Failure to refinance or extend this debt could materially impact operations.
- Permax Dependency: A substantial portion of 2001 revenue came from Permax. The company faces risks regarding the expiration of the primary composition patent and potential generic competition, though patent enforcement actions are underway.
- Licensor Financial Health: The development of Moraxen depends on CeNeS, which has experienced financial difficulties. Amarin may be forced to absorb development costs if CeNeS fails to fulfill obligations.
- Regulatory Approval: Future growth depends on FDA approvals for Zelapar and LAX-101, which are not guaranteed.
Investor Verification Checklist
- Debt Refinancing: Verify the status of refinancing the $45 million Elan loan due September 2002.
- Permax Option Exercise: Confirm receipt of consent from Eli Lilly to consummate the acquisition of Elan's full rights to Permax.
- Generic Competition: Monitor the status of Abbreviated New Drug Applications (ANDAs) for generic pergolide and the outcome of patent infringement lawsuits.
- CeNeS Viability: Assess the financial stability of CeNeS and the funding plan for Moraxen development.
- Regulatory Milestones: Track the FDA filing and approval status of Zelapar (expected H1 2002) and LAX-101 (expected H1 2003).